USC Scientists Create Renewable GMP Cancer Therapy, Slowing Tumors in Mice
Updated
Updated · ScienceDaily · Jun 29
USC Scientists Create Renewable GMP Cancer Therapy, Slowing Tumors in Mice
1 articles · Updated · ScienceDaily · Jun 29
Summary
USC researchers reported in Cell that granulocyte-monocyte progenitors can be expanded long term and engineered into a renewable source of cancer-fighting immune cells.
The GMP approach targets a key weakness of macrophage therapies: mature cells are hard to grow, modify, freeze and distribute widely in the body, especially for solid tumors.
In mouse studies, CAR-engineered GMPs settled in bone marrow, kept producing macrophages and other immune cells, and slowed both blood cancers and solid tumors; adding a second immune-activating signal strengthened the effect.
The extra signal still worked across donor-recipient immune mismatches, pointing to an off-the-shelf therapy made in advance rather than customized for each patient.
Beyond cancer, GMP treatment restored antibacterial immune function in mice with chronic granulomatous disease, suggesting broader use in immune deficiencies.
As rival NK cell therapies advance, can this new GMP platform truly win the race against solid tumors?
Could these self-renewing, cancer-fighting cells eventually trigger a new form of leukemia themselves?
2026 Breakthrough: Genetically Engineered GMPs Enable Universal, Long-Lasting Cancer Immunotherapy
Overview
In June 2026, scientists from USC and Stanford University made a major breakthrough by developing a renewable, expandable, and genetically engineered source of immune cell precursors called GMPs for cancer immunotherapy. This innovation addresses a key limitation of current treatments that require patient-specific cell generation. By creating an expandable source of these crucial immune cells, the approach makes cancer therapies more accessible and scalable. Importantly, the engineered cells remain effective even when donor and recipient are immunologically mismatched, paving the way for 'off-the-shelf' therapies that can be produced in advance and used for a wide range of patients.